var data={"title":"Amlodipine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amlodipine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5622?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amlodipine-drug-information\" class=\"drug drug_general\">see &quot;Amlodipine: Drug information&quot;</a> and <a href=\"topic.htm?path=amlodipine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amlodipine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133997\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Norvasc</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133998\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Accel-Amlodipine;</li>\n      <li>ACT-Amlodipine;</li>\n      <li>Amlodipine-Odan;</li>\n      <li>Apo-Amlodipine;</li>\n      <li>Auro-Amlodipine;</li>\n      <li>Bio-Amlodipine;</li>\n      <li>Dom-Amlodipine;</li>\n      <li>GD-Amlodipine;</li>\n      <li>JAMP-Amlodipine;</li>\n      <li>Mar-Amlodipine;</li>\n      <li>Mint-Amlodipine;</li>\n      <li>Mylan-Amlodipine;</li>\n      <li>Norvasc;</li>\n      <li>PHL-Amlodipine;</li>\n      <li>PMS-Amlodipine;</li>\n      <li>Q-Amlodipine;</li>\n      <li>RAN-Amlodipine;</li>\n      <li>ratio-Amlodipine;</li>\n      <li>Riva-Amlodipine;</li>\n      <li>Sandoz Amlodipine;</li>\n      <li>Septa-Amlodipine;</li>\n      <li>Teva-Amlodipine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051019\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antianginal Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Calcium Channel Blocker</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Calcium Channel Blocker, Dihydropyridine</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051012\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amlodipine-drug-information\" class=\"drug drug_general\">see &quot;Amlodipine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 5 years: Limited data available: <b>Note:</b> A population pharmacokinetic study found that children &lt;6 years of age had weight-adjusted clearance and V<sub>d</sub> of amlodipine that were significantly greater than children &ge;6 years of age. This may suggest the need for higher mg/kg/day doses in younger children (&lt;6 years of age); however, the study included only a small number of younger children (n=11) (Flynn 2006). One retrospective pediatric study (n=55) that included only eight patients 1-6 years of age used initial doses of 0.05-0.1 mg/kg/day; doses were titrated upwards as needed; mean required dose was significantly higher in patients 1-6 years of age (0.3 &plusmn; 0.16 mg/kg/day) compared to older children (6 to 12 years: 0.16 &plusmn; 0.12 mg/kg/day; 12 to 20 years: 0.14 &plusmn; 0.1 mg/kg/day) (Flynn 2000a).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 6 to 17 years: 2.5 to 5 mg once daily; doses &gt;5 mg daily have not been fully studied. In a randomized, placebo-controlled trial of amlodipine in children (n=268; mean age: 12.1 years; range: 6 to 16 years), a significant reduction in systolic blood pressure (compared to placebo) was observed in both the 2.5 mg once daily and the 5 mg once daily amlodipine groups. The authors recommend an initial dose of 0.06 mg/kg/day with a maximum dose of 0.34 mg/kg/day (not to exceed 10 mg/day) (Flynn 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coronary artery disease (CAD) (chronic stable angina, vasospastic angina, angiographically documented CAD [without heart failure or ejection fraction &lt;40%]):</b> Oral: 5 to 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> Oral: Initial: 5 mg once daily or 2.5 mg once daily in small or frail patients, or when adding amlodipine to other antihypertensive therapy; maximum daily dose: 10 mg/<b>day</b>. In general, titrate every 7 to 14 days. Titrate more rapidly, however, if clinically warranted, provided the patient is assessed frequently. Usual dosage range (ASH/ISH [Weber 2014]): 5 to 10 mg once daily. Target dose (JNC8 [James 2013]): 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &ge; 6 years, Adolescents, and Adults: No dosage adjustment necessary (Doyle 1989; Kungys 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on dialysis: Adults: Hemodialysis and peritoneal dialysis do not enhance elimination; supplemental dose is not necessary (Kungys 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coronary artery disease (CAD) (chronic stable angina, vasospastic angina, angiographically documented CAD without heart failure or ejection fraction &lt;40%): Initial: 5 mg once daily; titrate slowly in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypertension: Initial: 2.5 mg once daily; titrate slowly in patients with severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133971\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norvasc: 2.5 mg, 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133957\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50027145\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=amlodipine-drug-information\" class=\"drug drug_general\">see &quot;Amlodipine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">AmLODIPine Bes+SyrSpend SF oral suspension is available as a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051023\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133993\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051022\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hypertension (FDA approved in ages &ge;6 years and adults); chronic stable angina (FDA approved in adults); vasospastic (Prinzmetal's) angina (FDA approved in adults); angiographically documented CAD [to decrease risk of hospitalization (due to angina) and coronary revascularization procedure] (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134051\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AmLODIPine may be confused with aMILoride </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norvasc may be confused with Navane, Norvir, Vascor</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Norvasc [U.S., Canada, and multiple international markets] may be confused with Vascor brand name for imidapril [Philippines] and simvastatin [Malaysia, Singapore, and Thailand]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134049\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing (more common in females), palpitations, peripheral edema (more common in females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, drowsiness, fatigue, male sexual disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle cramps, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea, pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Acute interstitial nephritis (Ejaz 2000), anorexia, atrial fibrillation, bradycardia, cholestasis, conjunctivitis, depression, diarrhea, difficulty in micturition, diplopia, dysphagia, epistaxis, erythema multiforme, exfoliative dermatitis, extrapyramidal reaction, eye pain, female sexual disorder, gingival hyperplasia, gynecomastia, hepatitis, hot flash, hyperglycemia, hypersensitivity angiitis, hypersensitivity reaction, hypoesthesia, increased serum transaminases, increased thirst, insomnia, leukopenia, maculopapular rash, myalgia, nocturia, orthostatic hypotension, osteoarthritis, pancreatitis, paresthesia, peripheral ischemia, peripheral neuropathy, phototoxicity, purpura, rigors, tachycardia, thrombocytopenia, tremor, vasculitis, ventricular tachycardia, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133979\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to amlodipine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to other dihydropyridines; severe hypotension (SBP &lt;90 mm Hg); breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133961\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Angina/MI: Increased angina and/or MI have occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension: Symptomatic hypotension can occur; acute hypotension upon initiation is unlikely due to the gradual onset of action. Blood pressure must be lowered at a rate appropriate for the patient's clinical condition.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2 to 3 weeks of starting therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose; titrate slowly in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (ACCF/AHA [Gersh 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Initiate at a lower dose in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Titration: Peak antihypertensive effect is delayed; dosage titration should occur after 7 to 14 days on a given dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134037\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, CYP2A6 (weak), CYP2C9 (weak), CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133966\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12603&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.<b> Exceptions: </b>Fluconazole; Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of AmLODIPine. Management: Reduce amlodipine dose by at least 50% and monitor for increased amlodipine effects (eg, hypotension) if an antihepaciviral combination product is initiated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of AmLODIPine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of AmLODIPine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: AmLODIPine may increase the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide.  Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Calcium Channel Blockers.  Management: Avoid use of nimodipine or nifedipine with phenytoin. Monitor for phenytoin toxicity and/or decreased calcium channel blocker effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some US and Canadian calcium channel blockers contraindicate use with rifampin, however recommendations vary. Consult appropriate labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133994\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Grapefruit juice may modestly increase amlodipine levels. Management: Monitor closely with concurrent use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133982\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Amlodipine crosses the placenta. Cord blood concentrations were approximately one-third of maternal serum at delivery, and concentrations in the newborn were below the limit of quantification (&lt;0.1 ng/mL) when measured in eight infants within 48 hours of delivery (Morgan 2017). Information related to the use of amlodipine in pregnancy is limited (Ahn 2007; Nahapetian 2008; Vigil-De Gracia 2014; Yu 2015). Due to pregnancy induced pharmacologic changes, amlodipine pharmacokinetics may be altered immediately postpartum; large individual patient variability was observed (Naito 2015b).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, agents other than amlodipine are preferred (ACOG 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051018\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate, liver enzymes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133960\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133978\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Antihypertensive effect: Significant reductions in blood pressure at 24 to 48 hours after first dose; slight increase in heart rate within 10 hours of administration may reflect some vasodilating activity (Donnelly 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Antihypertensive effect: At least 24 hours (Donnelly 1993); has been shown to extend to at least 72 hours when discontinued after 6 to 7 weeks of therapy (Biston 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed (Meredith 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Mean V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;6 years: Similar to adults on a mg per kg basis; <b>Note: </b>Weight-adjusted V<sub>d</sub> in younger children (&lt;6 years of age) may be greater than in older children (Flynn 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 21 L/kg  (Scholz 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~93%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (~90%) to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 64% to 90% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal (biphasic): 30 to 50 hours; increased with hepatic dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (10% of total dose as unchanged drug, 60% of total dose as metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: May be decreased in patients with hepatic insufficiency or moderate to severe heart failure; weight-adjusted clearance in children &gt;6 years of age is similar to adults; <b>Note:</b> Weight-adjusted clearance in younger children (&lt;6 years of age) may be greater than in older children (Flynn 2006) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133977\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 1 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of simple syrup and 1% methylcellulose or a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg;. Crush fifty 5 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 250 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 250 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 56 days at room temperature or 91 days refrigerated.</p>\n    <div class=\"reference\">Nahata MC, Morosco RS, and Hipple TF, &quot;Stability of Amlodipine Besylate in Two Liquid Dosage Forms,&quot; <i>J Am Pharm Assoc (Wash)</i> 1999, 39(3):375-7.<span class=\"pubmed-id\">10363465</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133981\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (AmLODIPine Bes+SyrSpend SF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (120 mL): $196.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (AmLODIPine Besylate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (90): $155.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (90): $155.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $213.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Norvasc Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (90): $671.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $746.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $921.16</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133984\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A-B Vask (ID);</li>\n      <li>Actapin (HK, ID, SG);</li>\n      <li>Adipin (BD, VN);</li>\n      <li>Aforbes (PH);</li>\n      <li>Agen (CZ, EE, LV);</li>\n      <li>Aladyn (UA);</li>\n      <li>Alopine (TW);</li>\n      <li>Alozur (HU);</li>\n      <li>Amaday (PH);</li>\n      <li>Ambesyl (PH);</li>\n      <li>Amcal (PH);</li>\n      <li>Amcard (IN);</li>\n      <li>Amcardia (TH);</li>\n      <li>Amdepin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM);</li>\n      <li>Amdhapine (SG);</li>\n      <li>Amdipin (CO, PE);</li>\n      <li>Amdixal (ID);</li>\n      <li>Amedin (HK);</li>\n      <li>Amilo (TW);</li>\n      <li>Amlate (ZA);</li>\n      <li>Amlibon (MY);</li>\n      <li>Amlibon BES (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Amlo-H10 (ZW);</li>\n      <li>Amlo-H5 (ZW);</li>\n      <li>Amlo-M (KR);</li>\n      <li>Amlober (NL);</li>\n      <li>Amloc (AR, CL);</li>\n      <li>Amlocar (PE);</li>\n      <li>Amlocor (ZW);</li>\n      <li>Amlod (HK, TH);</li>\n      <li>Amlodac (MY, TW);</li>\n      <li>Amlodar (AE, KW, LB);</li>\n      <li>Amlode (IE);</li>\n      <li>Amlodigamma (HK);</li>\n      <li>Amlodin (JP);</li>\n      <li>Amlodine (LK, PH, TW);</li>\n      <li>Amloget (VN);</li>\n      <li>Amlogrix (ID);</li>\n      <li>Amlong (HK, MY, SG);</li>\n      <li>Amlopin (BD, HR, KR, PL);</li>\n      <li>Amlopine (TH);</li>\n      <li>Amlopres (HK);</li>\n      <li>Amlopress (SA);</li>\n      <li>Amlor (BE, EC, ES, FR, IL, LU, SA);</li>\n      <li>Amlorine (ET);</li>\n      <li>Amlostar (KR);</li>\n      <li>Amlosyn (CO);</li>\n      <li>Amlotan (IE);</li>\n      <li>Amlotens (SG);</li>\n      <li>Amlotrene (PH);</li>\n      <li>Amlovas (VN);</li>\n      <li>Amlovasc (CH);</li>\n      <li>Amlovasc 5 (TH);</li>\n      <li>Amlozen (HK);</li>\n      <li>Amodin (KR);</li>\n      <li>Amodipin (KR);</li>\n      <li>Amopress (QA);</li>\n      <li>Ampliron (PY);</li>\n      <li>Amtas (ET, SG);</li>\n      <li>Amvasc (AE, QA);</li>\n      <li>Amze (AR, PY);</li>\n      <li>An Nei Zhen (CN);</li>\n      <li>Anoldin (MY);</li>\n      <li>Anydipine (KR);</li>\n      <li>Ao Wan Lu (CN);</li>\n      <li>Arainno (ES);</li>\n      <li>Asomex-5.0 (ET);</li>\n      <li>Astudal (ES);</li>\n      <li>Avevasc (MY, SG);</li>\n      <li>Avistar (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Awar (ES);</li>\n      <li>Bezam (PH);</li>\n      <li>Cab (BD);</li>\n      <li>Calbivas (ID);</li>\n      <li>Calbloc (PH);</li>\n      <li>Calchek (IN, LK);</li>\n      <li>Calvase (NZ);</li>\n      <li>Cardilopin (VN);</li>\n      <li>Cardol (PH);</li>\n      <li>Cobisk (KR);</li>\n      <li>Comdipin (ID);</li>\n      <li>Cordarene (BR);</li>\n      <li>Covasc (LK, MY, PH);</li>\n      <li>CP-Lovac (HK);</li>\n      <li>Cydipin (ID);</li>\n      <li>DAILYvasc (PH);</li>\n      <li>Derox-5 (PH);</li>\n      <li>Deten (TH);</li>\n      <li>Dipsope (VN);</li>\n      <li>Du.Q (TW);</li>\n      <li>Duactin 5 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Ertensi (ID);</li>\n      <li>Evasc (KR);</li>\n      <li>Fulopin (ID);</li>\n      <li>Gensia (ID);</li>\n      <li>Gravask (ID);</li>\n      <li>Hovasc (HK, LK, MY);</li>\n      <li>Hypodipine (QA);</li>\n      <li>Istin (GB, IE, MT);</li>\n      <li>Istolde (IE);</li>\n      <li>Lama (IN);</li>\n      <li>Lodibes (PH);</li>\n      <li>Lodin (PH);</li>\n      <li>Lodipam (VN);</li>\n      <li>Lofral (HK, JO, MY, QA);</li>\n      <li>Lomanor (ZW);</li>\n      <li>Lotense (LB, MY);</li>\n      <li>Lovas (TH);</li>\n      <li>Lowdipine (KR);</li>\n      <li>Lowrac (QA);</li>\n      <li>Lupin (ID);</li>\n      <li>Narvin (TH);</li>\n      <li>Nexus (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Noloten (EC);</li>\n      <li>Nopidin (BD);</li>\n      <li>Nor-Lodipina (DO, GT, HN, NI, SV);</li>\n      <li>Nordip (AU);</li>\n      <li>Nordipine (MY);</li>\n      <li>Normodipine (HU, SG);</li>\n      <li>Norvapine (AU);</li>\n      <li>Norvas (CO, ES, MX);</li>\n      <li>Norvasc (AT, AU, BB, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ET, FI, GH, GM, GN, GR, GT, GY, HK, HN, HU, IL, IS, IT, JM, JO, JP, KE, KR, KW, LR, LT, LV, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);</li>\n      <li>Norvasc ODT (SG);</li>\n      <li>Norvask (ID, UA);</li>\n      <li>Novaspin (KR);</li>\n      <li>Odasyl (PH);</li>\n      <li>Opivask (ID);</li>\n      <li>Ozlodip (AU);</li>\n      <li>Perivasc (AU);</li>\n      <li>Prelod (TH);</li>\n      <li>Presilam (CL);</li>\n      <li>Provasc (PH);</li>\n      <li>Remedopin S (VN);</li>\n      <li>Sinnorvapin (KR);</li>\n      <li>Sinop (AR);</li>\n      <li>Sistopress (MX);</li>\n      <li>Stadovas (HK, MY);</li>\n      <li>Stamlo (SG, UA);</li>\n      <li>Stamlo-10 (LK);</li>\n      <li>Tenox (SG);</li>\n      <li>Tensivask (ID);</li>\n      <li>Terloc (PY);</li>\n      <li>Varodipine (SG);</li>\n      <li>Vascodipine (QA);</li>\n      <li>Vascor (JO);</li>\n      <li>Vasocal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vasotop (EC);</li>\n      <li>Vasten (CO);</li>\n      <li>Vazotal (UA);</li>\n      <li>Zynor (HK, MY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andersen J, Groshong T, and Tobias JD, &quot;Preliminary Experience With Amlodipine in the Pediatric Population,&quot; <i>Am J Ther</i>, 2006, 13(3):198-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/16772760/pubmed\" target=\"_blank\" id=\"16772760\">16772760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biston P, M&eacute;lot C, Degaute JP, Clement D, Quoidbach A. Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. <i>Blood Press</i>. 1999;8(1):43-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10412882 /pubmed\" target=\"_blank\" id=\"10412882 \">10412882 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donnelly R, Meredith PA, Miller SH, Howie CA, Elliott HL. Pharmacodynamic modeling of the antihypertensive response to amlodipine. <i>Clin Pharmacol Ther</i>. 1993;54(3):303-310.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/8375125 /pubmed\" target=\"_blank\" id=\"8375125 \">8375125 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doyle GD, Donohue J, Carmody M, Laher M, Greb H, Volz M. Pharmacokinetics of amlodipine in renal impairment. <i>Eur J Clin Pharmacol</i>. 1989;36(2):205-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/2524389 /pubmed\" target=\"_blank\" id=\"2524389 \">2524389 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT and Pasko DA, &ldquo;Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,&rdquo; <i>Pediatr Nephrol</i>, 2000, 15(3-4):302-16. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11149130/pubmed\" target=\"_blank\" id=\"11149130\">11149130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT, Nahata MC, Mahan JD Jr, et al, &quot;Population Pharmacokinetics of Amlodipine in Hypertensive Children and Adolescents,&quot; <i>J Clin Pharmacol</i>, 2006, 46(8):905-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/16855075/pubmed\" target=\"_blank\" id=\"16855075\">16855075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT, Newburger JW, Daniels SR, et al, &quot;A Randomized, Placebo-Controlled Trial of Amlodipine in Children With Hypertension,&quot; <i>J Pediatr</i>, 2004, 145(3):353-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/15343191/pubmed\" target=\"_blank\" id=\"15343191\">15343191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT, Smoyer WE, and Bunchman TE, &ldquo;Treatment of Hypertensive Children With Amlodipine,&rdquo; <i>Am J Hypertens</i>, 2000a, 13(10):1061-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11041159/pubmed\" target=\"_blank\" id=\"11041159\">11041159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(24):e783-831.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Josefsson M, Zackrisson AL, and Ahlner J, &ldquo;Effect of Grapefruit Juice on the Pharmacokinetics of Amlodipine in Healthy Volunteers,&rdquo; <i>Eur J Clin Pharmacol</i>, 1996, 51(2):189-93. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/8911887 /pubmed\" target=\"_blank\" id=\"8911887 \">8911887 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khattak S, Rogan JW, Saunders EF, et al, &ldquo;Efficacy of Amlodipine in Pediatric Bone Marrow Transplant Patients,&rdquo; <i>Clin Pediatr (Phila)</i>, 1998, 37(1):31-5. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/9475697/pubmed\" target=\"_blank\" id=\"9475697\">9475697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kungys G, Naujoks H, Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. <i>Eur J Clin Pharmacol</i>. 2003;59(4):291-295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/12845505 /pubmed\" target=\"_blank\" id=\"12845505 \">12845505 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meredith PA and Elliott HL, &quot;Clinical Pharmacokinetics of Amlodipine,&quot; <i>Clin Pharmacokinet</i>, 1992, 22(1):22-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/1532771/pubmed\" target=\"_blank\" id=\"1532771\">1532771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, Clinical Practice Guidelines, 2011, National Institutes of Health. Available at  <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &quot;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&quot; <i>Pediatrics</i>, 2004, 114(2 Suppl 4th Report):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norvasc (amlodipine) [prescribing information]. New York, NY: Pfizer; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker ML, Robinson RF, and Nahata MC, &ldquo;Amlodipine Therapy in Pediatric Patients With Hypertension,&rdquo; <i>J Am Pharm Assoc</i>, 2002, 42(1):114-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11833502/pubmed\" target=\"_blank\" id=\"11833502\">11833502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfammatter JP, Clericetti-Affolter C, Truttmann AC, et al, &ldquo;Amlodipine Once-Daily in Systemic Hypertension,&rdquo; <i>Eur J Pediatr</i>, 1998, 157(8):618-21. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/9727842/pubmed\" target=\"_blank\" id=\"9727842\">9727842</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rogan JW, Lyszkiewicz DA, Blowey D, et al, &ldquo;A Randomized Prospective Crossover Trial of Amlodipine in Pediatric Hypertension,&rdquo; <i>Pediatr Nephrol</i>, 2000, 14(12):1083-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11045391/pubmed\" target=\"_blank\" id=\"11045391\">11045391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther. 1997 Jan;10 Suppl 3:869-872.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/9126675 /pubmed\" target=\"_blank\" id=\"9126675 \">9126675 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverstein DM, Palmer J, Baluarte HJ, et al, &ldquo;Use of Calcium-Channel Blockers in Pediatric Renal Transplant Recipients,&rdquo; <i>Pediatr Transplant</i>, 1999, 3(4):288-92. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10562973/pubmed\" target=\"_blank\" id=\"10562973\">10562973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tallian KB, Nahata MC, Turman MA, et al, &ldquo;Efficacy of Amlodipine in Pediatric Patients With Hypertension,&rdquo; <i>Pediatr Nephrol</i>, 1999, 13(4):304-10. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/10454779/pubmed\" target=\"_blank\" id=\"10454779\">10454779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vincent J, Harris SI, Foulds G, et al, &ldquo;Lack of Effect of Grapefruit Juice on the Pharmacokinetics and Pharmacodynamics of Amlodipine,&rdquo; <i>Br J Clin Pharmacol</i>, 2000, 50(5):455-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11069440/pubmed\" target=\"_blank\" id=\"11069440\">11069440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Vigier RO, Franscini LM, Bianda ND, et al, &quot;Antihypertensive Efficacy of Amlodipine in Children With Chronic Kidney Diseases,&quot; <i>J Hum Hypertens</i>, 2001, 15(6):387-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amlodipine-pediatric-drug-information/abstract-text/11439313/pubmed\" target=\"_blank\" id=\"11439313\">11439313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12603 Version 255.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F133997\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F133998\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051019\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051012\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F133971\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F133957\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50027145\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051023\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F133993\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051022\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134051\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134049\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F133979\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F133961\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F134037\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F133966\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F133994\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F133982\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051018\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F133960\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F133978\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F133977\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F133981\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F133984\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12603|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amlodipine-drug-information\" class=\"drug drug_general\">Amlodipine: Drug information</a></li><li><a href=\"topic.htm?path=amlodipine-patient-drug-information\" class=\"drug drug_patient\">Amlodipine: Patient drug information</a></li></ul></div></div>","javascript":null}